C-RLFYCasma Therapeutics
autophagy, targeted degradation, PHLYT
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RLFY
C-RLFYC-RLFYautophagy, targeted degradation, PHLYT
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Casma Therapeutics presents the belief that disease progression can be countered by restoring cellular balance, framing its core stance as the idea that rebalancing cellular function can reverse the course of disease.
SourceCasma Therapeutics states that disease can be addressed by restoring cellular health and balance through autophagy-based medicines. The company presents autophagy as a natural cellular process that maintains homeostasis by clearing substrates, recycling them for energy, and building structures needed for healthy function, and it says these insights can be translated into treatments for rare genetic diseases and broader pathologies.
SourceCasma Therapeutics states that restoring cellular health can help reverse disease, and that autophagy is a fundamental cellular process that can be harnessed to restore homeostasis and produce new medicines across a broad range of diseases. The company presents autophagy induction as a mechanism supported by disease models and frames its work as translating these biological insights into treatments for rare genetic diseases and broader pathologies.
SourceCasma Therapeutics states that disease can be addressed by restoring cellular health and balance through autophagy. Its stated view is that autophagy is an essential cellular process that clears substrates, recycles them for energy, and builds structures needed for healthy function, and that inducing or translating insights from this process can restore homeostasis and lead to new treatments for rare genetic diseases and broader pathologies.
Source